Related Experiment Video
Updated: Aug 12, 2026

Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
Use of a prenylation inhibitor as a novel antiviral agent
J S Glenn1, J C Marsters, H B Greenberg
1Division of Gastroenterology, Stanford University School of Medicine and Veterans Administration Medical Center, Palo Alto, California 94305-5487, USA. Jeffrey.glen@stanford.edu
Abstract:
No specific therapy exists for hepatitis delta virus (HDV), which can cause severe liver disease. Molecular genetic studies have implicated the prenylation site of large delta antigen as a critical determinant of HDV particle assembly. We have established a cell culture model which produces HDV-like particles, and we show that delta antigen prenylation can be pharmacologically inhibited by the prenylation inhibitor BZA-5B. Furthermore, BZA-5B specifically abolishes particle production in a dose-dependent manner. These results demonstrate that the use of such a prenylation inhibitor-based antiviral therapy may be feasible and identify a novel class of potential antiviral agents.
More Related Videos
Related Concept Videos
Subviral Agents
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly

